Please Wait...

Bioclinica Appoints David Herron as Chief Executive Officer

Dr. John Hubbard, current CEO, assumes non-Executive Board of Directors role

November 29, 2017

DOYLESTOWN, Pa, – Bioclinica®, a world-leading provider of specialty clinical trial services, has appointed David Herron as the company's next Chief Executive Officer, effective January 2, 2018. This follows the planned retirement of current Chief Executive Officer, John Hubbard, PhD, who will remain as a non-Executive Director on the Bioclinica Board.

With more than 10 years' of experience at Bioclinica, David Herron has led the company's Medical Imaging business to great success. During his tenure, he integrated three of the industry's leading medical imaging companies (Bioclinica, Corelab Partners, and Synarc) into one comprehensive service provider. Focusing on both operational excellence and process efficiency, Herron has grown the business into the world’s largest independent supplier of medical imaging services for clinical trials.

Recently Herron assumed the additional responsibility of leading Bioclinica’s technology-focused eHealth segment, immediately creating new synergies that leverage Bioclinica's multi-faceted capabilities. With appointment to CEO, his oversight will extend to Bioclinica’s network of investigator sites and patient recruitment businesses for a unified clinical trial service offering unmatched in the industry.

Herron has more than 25 years' experience in healthcare technology, medical services and consulting, having worked at Ernst & Young, Caremark/CVS, HealthNet, and Webify Solutions/IBM.

David Herron

 

Dr. John Hubbard, current Chief Executive Officer of Bioclinica said, “It has been a privilege to serve as Chief Executive of Bioclinica for the past three years, however, now is the right time for me to take on a new role and welcome David to the Board.  This key transition has been core in our succession planning process. I've seen David successfully assume greater responsibility in the organization where he’s been integral in Bioclinica’s transformation over the last four years. I have every confidence in his ability to lead Bioclinica in the next phase of growth.”

 

David Herron

 

Herron commented, “I would like to thank John for his significant contribution as Chief Executive of Bioclinica for the last three years and I look forward to continue working with him in his new capacity as non-Executive Director. I am excited by the prospect of continuing to build and enhance Bioclinica's technology and service offering and working to help our clients improve clinical trial outcomes in the years ahead.”

About Bioclinica

Bioclinica is a global life sciences solution provider that utilizes science and technology to bring clarity to clinical trials – helping companies to develop new life-improving therapies more efficiently and safely. Successful clinical trials require the ability to see key details and uncover hidden insights, and Bioclinica’s hundreds of experienced scientific, medical, and domain experts bring unmatched insight across the development lifecycle, from the initial protocol to post-approval.  The company’s cloud-based offerings include medical imaging; cardiac safety; clinical adjudication; randomization and trial supply management and optimization; electronic and eSource data capture; site payments and forecasting; pharmacovigilance; trial management; and risk-based monitoring solutions. A true multifaceted partner to trial sponsors and Contract Research Organizations (CROs), Bioclinica offers an integrated App xChange partner ecosystem, a global network of research sites, patient recruitment services, and post-approval research expertise to provide committed, detail-focused service through all stages of drug development.  The company’s thousands of employees serve more than 400 pharmaceutical, biotechnology and device organizations – including all of the top 20 biopharmaceutical companies and leading CROs – through a network of offices in the U.S., Europe, and Asia.

Learn more about Bioclinica and our Clinical Adjudication and other offerings at www.Bioclinica.com and in the Bioclinica Blog. Follow the latest company news and happenings on LinkedIn and Twitter.

LEARN MORE OR SPEAK WITH OUR EXPERTS

CONTACT US
Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

Greetings from @DrugInfoAssn's DIA China from team @bioclinica : Haibing Xie; Shuang Zhou; Pencheng Ha; Angel Y.; M… https://t.co/m7cDDYEl5U
bioclinica (Yesterday)
Greetings from Beijing where David Kiger discussed the value of #AI in medical imaging along w optimization of EDC/… https://t.co/AJWNmaivpm
bioclinica (Yesterday)
We're hiring recent tech grads in #RTP for #pharma sector! Our innov. clinical financial solution gives our client… https://t.co/GHgOfszO0T
bioclinica (2 days ago)
Great to be @DrugInfoAssn DIA China! Ask us @bioclinica how sponsors & CROs can optimize electronic data capture… https://t.co/TtE4AiLnqY
bioclinica (2 days ago)
RT @bioclinica: Kinks in the clinical supply chain? Check out how one of our clients is using clinical supply optimization technology for m…
bioclinica (2 days ago)
RT @bioclinica: Welcoming everyone to KOP for #OCTEast Coast!!
bioclinica (2 days ago)

Latest Blogs:

Latin America: Benefit from the Right Partner
Removing Risk from Clinical Trial Management System (CTMS) Implementations
Collaboration Between Clinical Operations and the Logistics and Supply Chain Teams is Key to Trial Success
The Value of Protocol Review
CTMS and RBM: Hot Topics at OCT Nordics in Copenhagen